6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of May 2019

FRESENIUS MEDICAL CARE AG & Co. KGaA

(Translation of registrant’s name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F       xForm 40-F  o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  oNo   x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82

On May 2, 2019 Fresenius Medical Care AG & Co. KGaA (the “Company”) issued a Press Release announcing its first quarter results for the period ending March 31, 2019. A copy of the Press Release is furnished as Exhibit 99.1 and the corresponding financial figures as Exhibit 99.2.

The attached Press Release contains non-GAAP financial measures. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position, or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with generally accepted accounting principles. To supplement our first quarter 2019 consolidated financial results presented in accordance with International Financial Reporting Standards, or IFRS, we have used non-GAAP financial measure of (a) EBITDA, or operating income excluding interest, taxes, depreciation and amortization, (b) delivered operating income (earnings before interest and taxes), (c) free cash flow, and (d) results presented in constant currency. These non-GAAP measures are provided to enhance the user’s overall understanding of our current financial performance and our prospects for the future. In addition, because we have historically reported certain non-GAAP financial measures in our financial results, we believe the inclusion of these non-IFRS financial measures provides consistency and comparability in our financial reporting to prior periods for which these non-GAAP financial measures were previously reported. These non-GAAP financial measures should not be used as a substitute for or be considered superior to GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most comparable IFRS financial measures are included in the attached Press Release in a separate statement setting forth the reconciliation and in the Cash Flow Statement.

The Exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: May 2, 2019
	FRESENIUS MEDICAL CARE AG & Co. KGaA,
	a partnership limited by shares, represented by:
	FRESENIUS MEDICAL CARE MANAGEMENT AG, its
	General Partner
	By:	/s/ RICE POWELL
		Name:	Rice Powell
		Title:	Chief Executive Officer and
			Chairman of the Management Board
			of the General Partner
	By:	/s/ MICHAEL BROSNAN
		Name:	Michael Brosnan
		Title:	Chief Financial Officer and
			Member of the Management Board
			of the General Partner

3

EX-99.1

Exhibit 99.1

Press Release Media Contact Matthias Link T +49 6172 609-2872 matthias.link@fresenius.com Contact for analysts and investors Dr. Dominik Heger T +49 6172 609-2601 dominik.heger@fmc-ag.com www.freseniusmedicalcare.com

May 2, 2019

Fresenius Medical Care with a good start into 2019

·Underlying business developed as expected

·Earnings supported by agreements that materialized earlier than planned

·Cost optimization program initiated

·Integration of NxStage successfully started

·Non-prosecution agreement concluded with U.S. government

·Outlook confirmed

Key figures (IFRS)

EUR million	Q1 2019	Q1 2018	Growth yoy		Growth yoy, cc
Revenue	4,133	3,976	4	%	-1	%
Revenue adjusted(1)	4,125	3,725	11	%	6	%
Operating income (EBIT)	537	497	8	%	3	%
Operating income (EBIT) adjusted(1)	551	506	9	%	4	%
Net income(2)	271	279	-3	%	-6	%
Net income adjusted(1),(2)	318	296	8	%	3	%
Basic earnings per share (in EUR)	0.88	0.91	-3	%	-7	%
Basic earnings per share adjusted (in EUR)(1)	1.04	0.96	8	%	3	%

cc = at constant currency

The outlook provided by Fresenius Medical Care refers to adjusted revenue and adjusted net income.

(1)  For a detailed reconciliation, please refer to the table at the end of the press release

(2)  Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA

1

“In the first quarter we achieved healthy organic growth across all regions,” said Rice Powell, Chief Executive Officer of Fresenius Medical Care. “All of our major initiatives are underway. We have completed the acquisition of NxStage, and started its integration process as well as an expansion of the infrastructure necessary for home dialysis. We are very well positioned to reach the investment milestones set for 2019, and to meet our full-year targets.”

Investment year underway

Fresenius Medical Care continues its investments in the USA to increase the number of treatments being carried out in a home setting. Investments in training facilities, education and distribution infrastructure are a part of the initiative.

Expanding the production facilities in China is underway to cover for the growing product demand in the country with the most dialysis patients worldwide. Fresenius Medical Care´s development of its footprint in the services business is also progressing including the acquisition of selected hospitals to support renal care and the construction of clinics.

The investments of around EUR 100 million in 2019 as part of the Cost Optimization Program include as a major part the optimization of the US services footprint. The corresponding investments will ramp-up throughout the remainder of the year.

Key financials developed in line with expectations

Revenue in the first quarter 2019 increased by 4% to EUR 4,133 million (-1% at constant currency). Adjusted for the Q1 2018 revenue contribution from Sound Inpatient Physicians (“Sound”, divested effective end of Q2 2018) as well as the impact from the IFRS 16 implementation and the revenue contribution from NxStage following the closing, revenue increased by 11% (+6% at constant currency). Health Care Services revenue increased by 3% to EUR 3,317 million (-2% at constant currency). The decrease at constant currency was largely due to decreases attributable to prior year activities associated with Sound as well as the effect of closed or sold clinics and a decrease in dialysis days, partially offset by growth in same market treatments, increases in organic revenue per treatment and contributions from acquisitions. Health Care Products revenue increased by 6% to EUR 816 million (+4% at constant currency), mainly driven by higher sales of home hemodialysis products, largely as a result of the NxStage acquisition, dialyzers, products for acute care treatments, solutions and concentrates, and bloodlines, partially offset by lower sales of machines as a result of changes in the accounting treatment of sale-leaseback transactions related to the IFRS 16 implementation.

Total EBIT increased by 8% and reached EUR 537 million (+3% at constant currency), resulting in an operating margin of 13.0% (+50 basis points). On an adjusted basis, EBIT

2

increased by 9% (+4% at constant currency). The adjusted EBIT margin decreased from 13.6% to 13.4% (-20 basis points).

Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA decreased by 3% to EUR 271 million (-6% at constant currency). On an adjusted basis, net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA increased by 8% (+3% at constant currency).

Earnings growth in the first quarter was supported by agreements that have been realized earlier in the year than planned. In North America the annual positive impact from income attributable to a consent agreement on certain pharmaceuticals supported the earnings growth. In EMEA earnings growth was supported by the reduction of a contingent consideration liability related to Xenios, which was under discussion at the time the outlook for 2019 was issued.

Based on the number of approximately 306.7 million shares (weighted average number of shares outstanding), basic earnings per share (EPS) decreased by 3% to EUR 0.88       (-7% at constant currency). On an adjusted basis, basic EPS amounted to EUR 1.04, representing an increase of 8% (+3% at constant currency).

Healthy organic growth across all regions

North America revenue, which represents 70% of total revenue, increased by 4% to EUR 2,887 million (-4% at constant currency). Organic growth in North America was 6%. Health Care Services revenue increased by 3% to EUR 2,680 million (-4% at constant currency). On an adjusted basis, Health Care Services revenue increased by 14% (+6% at constant currency), driven by a 14% increase of Dialysis Care revenue to EUR 2,372 million (+6% at constant currency). The positive development at constant currency was mainly driven by increases in organic revenue per treatment, growth in same market treatments and contributions from acquisitions, partially offset by the impact of one less dialysis day. Same-market treatment growth in the US was 3.7%, a sequential improvement of 40 basis points. Care Coordination revenue decreased by 40% to EUR 308 million (-45% at constant currency), mainly due to the divestiture of Sound. On an adjusted basis, Care Coordination revenue increased by 17% to EUR 308 million (+8% at constant currency), mainly driven by increased member months for health plan services and increased volumes for vascular services.

As of the end of March 2019, the company was treating 205,775 patients (+4%) at its 2,559 clinics (+6%) in North America. Dialysis treatments increased by 3%.

3

Key figures North America

EUR million	Q1 2019		Q1 2018		growth		growth cc
Revenue	2,887		2,774		4	%	-4	%
Revenue adjusted	2,879		2,523		14	%	5	%
EBIT	372		362		3	%	-4	%
EBIT adjusted	390		371		5	%	-1	%
EBIT margin adjusted	13.6	%	14.7	%	—		—

In the U.S., the average revenue per treatment increased by USD 7 to USD 355 (+2%). The increase was mainly driven by higher utilization of calcimimetics and an increase in the ESRD PPS base rate, partially offset by lower revenue from commercial payors.

Cost per treatment in the U.S., adjusted for the implementation of IFRS 16, increased from USD 289 to USD 301 (+4%). This increase was largely driven by higher utilization of calcimimetics and higher personnel expense.

Health Care Products revenue increased by 12% to EUR 207 million (+4% at constant currency) due to higher sales of home hemodialysis products, products for acute care, and bloodlines, all largely as a result of the NxStage acquisition, partially offset by lower sales of machines as a result of changes in the accounting treatment of sale-leaseback transactions related to the IFRS 16 implementation.

Total EBIT of the North America segment increased by 3% to EUR 372 million (-4% at constant currency), resulting in an EBIT margin of 12.9% compared to 13.1% in the first quarter 2018. The EBIT margin decrease was mainly driven by higher personnel expense, the integration of and operational costs associated with NxStage and an unfavourable impact from legal settlements, partially offset by the positive impact from income attributable to a consent agreement on certain pharmaceuticals, increases in the Care Coordination margin, a favourable effect from the IFRS 16 implementation and a favourable impact from manufacturing. On an adjusted basis, EBIT increased by 5% (-1% at constant currency). The adjusted EBIT margin was 13.6% compared to 14.7% in the first quarter 2018.

EMEA revenue increased by 3% to EUR 653 million (+4% at constant currency), driven by a positive business development in both Health Care Services and Health Care Products. Organic growth was 4%. Health Care Services revenue increased by 3% to EUR 324 million (+5% at constant currency), resulting from growth in same market treatments, contributions from acquisitions and increases in organic revenue per treatment, partially offset by the impact of one less dialysis day. Health Care Products revenue increased by 2% to EUR 329 million (+3% at constant currency). Dialysis Product revenue increased by 3% (+3% at constant currency) mainly due to higher sales of machines and dialyzers,

4

hemodialysis solutions and concentrates as well as renal pharmaceuticals, partially offset by lower sales of products for acute care treatments. Non-Dialysis Products revenue decreased by 3% to EUR 19 million (-3% at constant currency).

EBIT increased by 26% to EUR 138 million (+27% at constant currency). Consequently, the EBIT margin was 21.1%, an increase from 17.1% in the first quarter 2018, mainly driven by a reduction of a contingent consideration liability related to Xenios, partially offset by higher bad debt expense, higher rent expense, and the impact from one less dialysis day.

As of the end of March 2019, the company was treating 65,833 patients (+4%) at its 782 clinics (+4%) in the EMEA region. Dialysis treatments increased by 4%.

Asia-Pacific revenue increased by 9% to EUR 428 million (+6% at constant currency), driven by a positive business development in both Health Care Services and Health Care Products. Organic growth was 6%. Health Care Services revenue increased by 8% to EUR 199 million (+4% at constant currency). Dialysis Care revenue increased by 7% to EUR 147 million (+1% at constant currency), mainly as a result of growth in same market treatments and contributions from acquisitions, partially offset by missing contributions from closed or sold clinics, a decrease in organic revenue per treatment and a decrease in dialysis days. Care Coordination revenue increased by 14% to EUR 52 million (+12% at constant currency), driven by contributions from acquisitions and organic revenue growth. Health Care Products revenue grew by 10% to EUR 229 million (+8% at constant currency), mainly driven by increased sales of dialyzers and machines.

EBIT increased by 28% to EUR 95 million (+25% at constant currency). The resulting EBIT margin was 22.1% (Q1 2018: 19.0%), mainly driven by favorable foreign currency transaction effects and a positive impact from business growth.

As of the end of March 2019, the company was treating 31,674 patients (+5%) at its 398 clinics in the Asia-Pacific region (+3%). Dialysis treatments increased by 4%.

Latin America delivered revenue of EUR 161 million, a decrease of 5%, but a significant increase of 14% at constant currency. Organic growth was 13%. Health Care Services revenue decreased by 5% to EUR 114 million (+20% at constant currency). The increase at constant currency was mainly a result of increases in organic revenue per treatment and contributions from acquisitions. Health Care Products revenue decreased by 5% to EUR 47 million (+1% at constant currency).

EBIT decreased by 19% to EUR 11 million (-24% at constant currency). The resulting EBIT margin was 7.1% (Q1 2018: 8.3%). The decline was mainly driven by hyperinflation in Argentina.

5

As of the end of March 2019, the company was treating 33,434 patients (+6%) at its 232 clinics in Latin America (+0%). Dialysis treatments increased by 4%.

Net interest expense increased in the first quarter by 30% to EUR 108 million (+24% at constant currency). The increase was primarily due to the IFRS 16 implementation and the acquisition of NxStage, partially offset by the replacement of high interest bearing senior notes repaid in 2018 by debt instruments at lower interest rates and interest income from the investment of the Sound proceeds. Income tax expense increased by 20% to EUR 101 million for the first quarter of 2019, which translates into an effective tax rate of 23.5% (Q1 2018: 20.3%). The increase was largely driven by the prior year impact in 2018 caused by favorable implications of the US tax reform.

Cash flow in line with expectations

The company generated EUR 76 million of operating cash flow (Q1 2018: EUR -45 million). The increase was largely driven by the IFRS 16 implementation leading to a reclassification of the repayment portion of rent to financing activities. The number of days sales outstanding (DSOs) increased to 83 days as compared to 75 days at December 31, 2018. Free cash flow (net cash used in operating activities, after capital expenditures, before acquisitions and investments) amounted to EUR -123 million (Q1 2018: EUR -263 million). Free cash flow was -3.0% of revenue (Q1 2018: -6.6%).

Outlook confirmed(3),(4)

For 2019, Fresenius Medical Care expects adjusted revenue to grow between 3% and 7% and adjusted net income(2) to develop in the range of -2% to 2%.

For 2020, Fresenius Medical Care expects adjusted revenue as well as adjusted net income(2) to grow at a mid to high single digit rate.

In order to make the business performance in the respective periods comparable these targets as well as the 2018 base are and will be adjusted for items such as: FCPA Related Charges, the IFRS 16 implementation, the contributions from Sound in the first half year of 2018, the gain (loss) related to divestitures of Care Coordination activities and expenses for the implementation of the cost optimization program. All effects from the acquisition of NxStage Medical Inc. are excluded from the targets for 2019 and 2020.

(3)Numbers at constant currency

(4)Reported revenue 2018 of EUR 16,547 million adjusted for Sound H1 2018; reported net income 2018 of EUR 1,982 million adjusted for Sound H1 2018, the gain (loss) related to divestitures of Care Coordination activities and the 2018 FCPA related charge

6

NxStage Update

The table below shows the previously communicated estimated effects of the NxStage acquisition on Fresenius Medical Care´s outlook for 2019 and 2020. The numbers exclude effects from the IFRS 16 implementation and integration costs of approximately EUR 50 to 75 million over the three years following the closing of the transaction. The company assumes the full year effect of incremental intangible assets amortization to be in the range of EUR 70 to 80 million for the first two years, then drop to EUR 45 to 55 million thereafter. The company will update estimates after a detailed assessment, if required.

EUR million	2019	2020
Revenue	240 to 260	310 to 330
Operating income (EBIT)	(30) to (20)	20 to 30
Interest	(75) to (65)	(85) to (75)
Net Income	(75) to (65)	(40) to (30)

2019 estimates cover the period starting on February 21, 2019 (closing date) until year-end 2019.

Fast implementation of the share buy-back program

In March 2019 Fresenius Medical Care started the first phase of its announced share buy-back program. The first phase runs from March 12, 2019 to May 10, 2019. It allows for a maximum of 6,000,000 shares to be repurchased. Until March 31, 2019, Fresenius Medical Care repurchased 1,629,240 shares, for an average stock price of EUR 69.86.

Non-prosecution agreement concluded with U.S. government

In March 2019, Fresenius Medical Care entered into a Non-Prosecution Agreement with the U.S. Department of Justice and a separate agreement with the Securities and Exchange Commission to resolve matters governed by the U.S. Foreign Corrupt Practices Act (FCPA). In 2012, the Company had voluntarily notified the U.S. government about internal investigations into conduct in countries outside the U.S. that might violate the FCPA.

Number of employees increased

As of March 31, 2019, Fresenius Medical Care had 118,308 employees (full-time equivalents) worldwide, compared to 114,831 employees at the end of March 2018. This increase of 3% was mainly attributable to the NxStage acquisition.

7

Conference call

Fresenius Medical Care will host a conference call to discuss the results of the first quarter today at 3:30 p.m. CEDT / 9:30 a.m. EDT. Details will be available on the company’s website www.freseniusmedicalcare.com in the “Investors/Events” section. A replay will be available shortly after the call.

Please refer to our statement of earnings included at the end of this news and to the attachments as separate PDF-files for a complete overview of the results for the first quarter 2019.

Fresenius Medical Care is the world’s leading provider of products and services for individuals with renal diseases of which around 3.4 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,971 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 336,716 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company’s website at www.freseniusmedicalcare.com.

Disclaimer

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

8

9

10

EX-99.2

Exhibit 99.2

Fresenius Medical Care AG & Co. KGaA COMPLETE OVERVIEW OF THE RESULTS FOR THE FIRST QUARTER 2019 May 2, 2019 Investor Relations phone: +49 6172 609 2525 email: ir@fmc-ag.com Content: Statement of earnings Segment information Balance sheet Cash flow Revenue development Key metrics Quality data Reconciliation Reconciliation non-IFRS page 2 page 3 page 4 page 5 page 6 page 7 page 8 page 9 page 10 Disclaimer This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release. Copyright by Fresenius Medical Care AG & Co. KGaA

Statement of earnings in € million, except share data, unaudited Three month ended March 31 at cc Health Care Products 816 767 6.3% 4.3% Gross profit 1,266 1,203 5.2% 0.2% (Gain) loss related to divestitures of Care Coordination activities - 13 n.a. n.a. Income from equity method investees (20) (18) 11.9% 11.5% Operating income margin in % 13.0% 12.5% Interest income (28) (25) 12.5% 9.4% Interest expense, net 108 83 30.0% 23.6% Income tax expense 101 84 19.8% 15.3% Net income attributable to noncontrolling interests 57 51 11.4% 3.3% Depreciation and amortization 362 175 107.1% 96.6% EBITDA margin in % 21.8% 16.9% Weighted average number of shares 306,659,364 306,453,070 Basic earnings per share €0.88 €0.91 -2.9% -6.5% Based on the IFRIC agenda decision relating to the applicability of IAS 12 to the accounting for interest and penalties related to income taxes and an interpretation issued by the Accounting Standards Committee of Germany (ASCG) approved in September 2018 interest and penalties related to income taxes have been reclassified from income tax expense to interest expense, net in the amount of €3 million for the three months ended March 31, 2018. Statement of earnings page 2 of 10 May 2, 2019 Basic earnings per ADS€0.44€0.45-2.9%-6.5% EBITDA89967233.8%27.6% Operating income (EBIT)5374978.0%3.2% Net income attributable to shareholders of FMC-AG & Co. KGaA271279-2.8%-6.5% Net income328330-0.6%-5.0% Income before taxes4294143.6%-0.8% Interest expense13610826.0%20.3% Operating income (EBIT)5374978.0%3.2% Research and development34325.4%3.0% Selling, general and administrative7156795.4%0.0% Costs of revenue2,8672,7733.4%-1.3% Total revenue4,1333,9763.9%-0.8% Health Care Services3,3173,2093.4%-2.1% 20192018ChangeChange

Segment information unaudited Three month ended March 31 at cc Revenue in € million 4,133 3,976 3.9% -0.8% Operating income margin in % 13.0% 12.5% Days sales outstanding (DSO) 83 85 Revenue in € million 2,887 2,774 4.0% -3.9% Operating income margin in % 12.9% 13.1% Days sales outstanding (DSO) 72 73 U.S. Cost per dialysis treatment in US$ 1 301 289 4.0% n.a. EMEA Operating income (EBIT) in € million 138 109 26.5% 27.3% Delivered EBIT in € million 136 108 26.1% 26.9% Revenue in € million 428 392 9.2% 5.9% Operating income margin in % 22.1% 19.0% Days sales outstanding (DSO) 117 117 Latin America Operating income (EBIT) in € million 11 14 -19.3% -24.2% Delivered EBIT in € million 11 14 -21.3% -26.4% Revenue in € million 4 4 14.4% 14.2% Delivered EBIT in € million (79) (62) 27.4% 25.1% 1 2019 excluding the effects from the implementation of IFRS 16 cc = constant currency. Changes in revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items include the impact of changes in foreign currency exchange rates. We calculate these non-IFRS financial measures at constant exchange rates to show changes in our revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items without giving effect to period-to-period currency fluctuations. Under IFRS, amounts received in local (non-euro) currency are translated into euro at the average exchange rate for the period presented. Once we translate the local currency for the constant currency, we then calculate the change, as a percentage, of the current period using the prior period exchange rates versus the prior period. The single quarter results are calculated as the variance between the current year-to-date results less the preceding quarter’s year-to-date which makes the single quarter subject to further foreign exchange fluctuation. This resulting percentage is a non-IFRS measure referring to a change as a percentage at constant currency. These currency-adjusted financial measures are identifiable by the designated term "Constant Currency". We believe that the non-IFRS financial measure Constant Currency is useful to investors, lenders and other creditors because such information enables them to gauge the impact of currency fluctuations on a company’s revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items from period to period. However we limit our use of Constant Currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency into euro. We do not evaluate our results and performance without considering both Constant Currency period-over-period changes in non-IFRS revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items and changes in revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items prepared in accordance with IFRS. We caution the readers of this report to follow a similar approach by considering data on Constant Currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items prepared in accordance with IFRS. We present the growth rate derived from IFRS measures next to the growth rate derived from non-IFRS measures such as revenue, operating income, net income attributable to shareholders of FMC-AG & Co. KGaA and other items. As the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit. Segment information page 3 of 10 May 2, 2019 Operating income (EBIT) in € million (79) (62) 27.3% 25.1% Corporate Days sales outstanding (DSO) 120129 Operating income margin in % 7.1% 8.3% Revenue in € million 161170-5.2% 14.2% Delivered EBIT in € million 937228.6% 25.6% Operating income (EBIT) in € million 957427.6% 24.5% Asia-Pacific Days sales outstanding (DSO) 96103 Operating income margin in % 21.1% 17.1% Revenue in € million 6536362.6% 4.1% Revenue per dialysis treatment in US$ 3553482.1% n.a. Delivered EBIT in € million 3193141.6% -4.4% Operating income (EBIT) in € million 3723622.8% -3.5% North America Employees (full-time equivalents) 118,308114,831 Delivered EBIT in € million 4804467.6% 3.2% Operating income (EBIT) in € million 5374978.0% 3.2% Total 2019 2018 Change Change

Balance sheet in € million, except net leverage ratio March 31 March 31 December 31 (unaudited) (unaudited) (audited) Current assets 7,501 7,847 Right of use assets 4,311 - Total assets 32,353 26,242 Liabilities and equity Non-current liabilities 11,763 7,072 Total liabilities and equity 32,353 26,242 Equity/assets ratio 41% 49% Debt Short-term debt from related parties 107 107 189 Current portion of long-term lease liabilities 615 - - Long-term debt, less current portion 5,681 5,690 5,045 Long-term lease liabilities from related parties, less current portion 117 - - Cash and cash equivalents 959 959 2,146 Total net debt 12,273 7,674 5,400 Annualized EBITDA1 2,898 2,244 2,215 Operating income (EBIT) Non-cash charges 45 45 45 Annualized EBITDA 3,880 3,059 2,976 1 EBITDA : including largest acquisitions and divestitures and excluding the gain related to divestitures of Care Coordination activities and NxStage related transaction costs. Balance sheet page 4 of 10 May 2, 2019 Net leverage ratio3.22.51.8 Depreciation and amortization 937770716 Total debt13,2328,6337,546 Long-term lease liabilities, less current portion 3,864--Current portion of long-term lease liabilities from related parties 16--Current portion of long-term debt1,5121,5161,107 Short-term debt1,3201,3201,205 excluding IFRS 16 implementation Total equity 13,22712,902 Current liabilities 7,3636,268 Other non-current assets5,5485,504 Goodwill and intangible assets14,99312,891 Assets 201920192018

Cash flow statement in € million, unaudited Three month ended March 31 Operating activities Depreciation / amortization 362 175 Net cash provided by (used in) operating activities 76 -45 Purchases of property, plant and equipment (201) (221) Capital expenditures, net (199) (218) Free cash flow (123) (263) Proceeds from divestitures 11 - Free cash flow after investing activities (1,941) (444) Cash flow page 5 of 10 May 2, 2019 Acquisitions and investments, net of divestitures(1,818)(181) Acquisitions and investments, net of cash acquired, and purchases of intangible assets(1,829)(181) In percent of revenue-3.0%-6.6% Proceeds from sale of property, plant and equipment23 Investing activities In percent of revenue1.8%-1.1% Change in working capital and other non-cash items(614)(550) Net income328330 20192018

Revenue development Same market treatment growth1 in € million, unaudited Change at cc Organic growth 2019 2018 Change Three month ended March 31 Health Care Services 3,317 3,209 3.4% -2.1% 6.3% 3.5% Thereof Care Coordination revenue 360 561 -35.8% -40.1% 7.0% 3.7%2 Health Care Services 2,680 2,590 3.5% -4.4% 6.0% Thereof Dialysis Care revenue 2,372 2,075 14.3% 5.6% 5.8% 3.7%2 Thereof Care Coordination revenue 308 515 -40.2% -44.7% 7.4% Health Care Services 324 314 3.1% 5.2% 4.6% 3.9% Thereof Dialysis Products 310 302 2.5% 3.3% 3.7% Health Care Services 199 184 8.3% 3.9% 5.0% 7.1% Thereof Care Coordination revenue 52 46 13.8% 11.7% 4.8% Health Care Services 114 121 -5.2% 19.6% 17.2% 0.7% 1 same market treatment growth = organic growth less price effects 2 U.S. (excl. Mexico), same market treatment growth North America: 3.3% for the three months ended March 31 2019 Revenue development page 6 of 10 May 2, 2019 Corporate4414.4%14.2% Health Care Products4749-5.2%0.9%1.1% Latin America161170-5.2%14.2%12.5% Health Care Products22920810.0%7.7%7.7% Thereof Dialysis Care revenue1471386.5%1.3%5.1%7.1% Asia-Pacific4283929.2%5.9%6.5% Thereof Non-Dialysis Products1920-3.0%-3.0%-3.0% Health Care Products3293222.2%3.0%3.3% EMEA6536362.6%4.1%3.9% Health Care Products20718412.2%3.7%5.5% North America2,8872,7744.0%-3.9%6.0% Health Care Products8167676.3%4.3%4.9% Thereof Dialysis Care revenue2,9572,64811.7%6.0%6.2%3.5% Total revenue4,1333,9763.9%-0.8%6.0%

Key metrics North America segment unaudited Three month ended March 31 at cc Revenue in € million 2,579 2,259 14.1% 5.5% Operating income (EBIT) in € million 332 349 -4.7% -10.4% Operating income margin in % 12.9% 15.4% Delivered EBIT in € million 285 304 -6.4% -11.7% Revenue in € million 308 515 -40.2% -44.7% Operating income margin in % 13.0% 2.6% Key metrics Care Coordination unaudited Three month ended March 31 at cc North America Member months under medical cost management1 170,903 165,797 3.1% Medical cost under management (in € million)1 1,071 1,189 -9.9% -16.8% 1 The metrics may be understated due to a physician mapping issue related to the BPCI program within a CMS system which has not yet been resolved. Additionally, data presented for the BPCI and ESCO metrics are subject to finalization by CMS, which may result in changes from previously reported metrics. Key metrics Dialysis Care Services unaudited Three month ended March 31 in % in % in % Total 3,971 5% 29 336,716 4% 12,561,531 3% North America 2,559 6% 15 205,775 4% 7,707,848 3% EMEA 782 4% 4 65,833 4% 2,475,702 4% Asia-Pacific 398 3% 8 31,674 5% 1,099,404 4% Key metrics page 7 of 10 May 2, 2019 Latin America2320%233,4346%1,278,5774% ClinicsGrowthDe novosPatientsGrowthTreatmentsGrowth Care Coordination patient encounters1272,3531,957,694-86.1% 20192018ChangeChange Delivered EBIT in € million3410253.0%226.2% Operating income (EBIT) in € million4013202.8%179.8% Care Coordination Dialysis 20192018ChangeChange

Quality data1 in % of patients North America EMEA Latin America Asia-Pacific % of patients Q1 2019 Q1 2018 Q1 2019 Q1 2018 Q1 2019 Q1 2018 Q1 2019 Q1 2018 Kt/V > 1.2 97 97 94 95 90 92 95 96 Hemoglobin = 10–12 g/dl 70 71 82 83 49 52 56 57 Calcium = 8.4–10.2 mg/dl 85 85 79 80 77 78 74 74 Albumin > 3.5 g/dl 81 80 89 88 91 90 90 89 Phosphate < 5.5 mg/dl 60 62 80 81 76 76 66 68 in days 1 Definitions of quality parameters cf. Annual Report 2018, Section "Non-Financial Group Report" (page 87) Quality data page 8 of 10 May 2, 2019 Days in hospital per patient year10.3117.57.84.343.03.6 Patients without catheter (after 90 days)8383798080808587

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures Three month ended March 31 in € million, unaudited Delivered EBIT reconciliation Operating income (EBIT) 537 497 Delivered EBIT 480 446 North America less noncontrolling interests (53) (48) Operating income (EBIT) 332 349 Delivered EBIT 285 304 Care Coordination less noncontrolling interests (6) (3) Operating income (EBIT) 138 109 Delivered EBIT 136 108 Asia-Pacific less noncontrolling interests (2) (2) Operating income (EBIT) 89 68 Delivered EBIT 87 66 Care Coordination less noncontrolling interests 0 0 Operating income (EBIT) 11 14 Delivered EBIT 11 14 Corporate less noncontrolling interests 0 0 Reconciliation of net cash provided by operating activities to EBITDA1 899 672 Total EBITDA Income tax expense (101) (84) Net cash provided by operating activities 76 (45) 1 EBITDA is the basis for determining compliance with certain covenants in Fresenius Medical Care's long-term debt instruments. Reconciliation page 9 of 10 May 2, 2019 Change in working capital and other non-cash items(614)(550) Interest expense, net(108)(83) Delivered EBIT(79)(62) Operating income (EBIT)(79)(62) less noncontrolling interests00 Latin America Delivered EBIT66 Operating income (EBIT)66 less noncontrolling interests(2)(2) Dialysis Delivered EBIT9372 Operating income (EBIT)9574 less noncontrolling interests(2)(1) EMEA Delivered EBIT3410 Operating income (EBIT)4013 less noncontrolling interests(47)(45) Dialysis Delivered EBIT319314 Operating income (EBIT)372362 less noncontrolling interests(57)(51) Total 20192018

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures in € million, except share data, unaudited (Gain) loss related to divestitures of Care Coordination activities Cost NxStage optimization Results 2019 Adjusted Results 2018 Adjusted Change (adjusted results) Change (adjusted results) at cc Sound Q11 Results IFRS 16 NxStage operations Results 2018 2019 Implementation costs costs Three month ended March 31 Total revenue 4,133 22 (30) 4,125 3,976 (251) 3,725 10.7% 5.6% Health Care Services 3,317 (1) 3,316 3,209 (251) 2,958 12.1% 6.2% Health Care Products 816 22 (29) 809 767 767 5.5% 3.6% North America 2,887 22 (30) 2,879 2,774 (251) 2,523 14.1% 5.4% Health Care Services 2,680 (1) 2,679 2,590 (251) 2,339 14.5% 5.8% thereof Dialysis Care 2,372 (1) 2,371 2,075 2,075 14.2% 5.6% thereof Care Coordination 308 308 515 (251) 264 16.5% 7.7% Health Care Products 207 22 (29) 200 184 184 8.6% 0.4% EBITDA 899 (184) 3 16 4 738 672 (9) 13 676 9.2% 4.3% Total operating income (EBIT) 537 (17) 11 16 4 551 497 (4) 13 506 9.0% 4.1% North America 372 (13) 11 16 4 390 362 (4) 13 371 5.2% -1.3% 332 Dialysis (11) 11 16 4 352 349 349 1.0% -5.2% Care Coordination 40 (2) 38 13 (4) 13 22 72.4% 59.3% 138 EMEA (1) 137 109 109 25.8% 26.7% Asia-Pacific 95 (1) 94 74 74 26.4% 23.3% Dialysis 89 (1) 88 68 68 29.8% 26.4% Care Coordination 6 0 6 6 6 -10.6% -10.2% Latin America 11 0 11 14 14 -20.9% -27.0% Corporate (79) (2) (81) (62) (62) 29.4% 27.0% Income tax expense 101 7 5 4 1 118 84 2 86 36.6% 30.9% Net income2 271 18 14 12 3 318 279 4 13 296 7.6% 3.1% 1 Contribution of Sound Physicians 2 Attributable to shareholders of FMC-AG & Co. KGaA Reconciliation non-IFRS page 10 of 10 May 2, 2019 Basic earnings per share€0.88€0.06€0.05€0.04€0.01€1.04€0.91€0.01€0.04€0.967.5%3.0% Net income attributable to noncontrolling interests5757515111.3%3.1% Interest expense, net108(42)(8)5883(10)73-19.5%-23.0%